Company (location)

Product

Description

Indication

Status

Date


Achaogen Inc. (South San Francisco)

Plazomicin

Aminoglycoside antibiotic

Complicated urinary tract infection, including acute pyelonephritis

Phase III EPIC study comparing plazomicin to meropenem showed that plazomicin demonstrated a composite cure rate of 72% vs. 56.5% (difference [plazomicin minus meropenem]: 15.5, 95% CI: -13.7 to 41.9)

6/6/17

Aridis Pharmaceuticals Inc. (San Jose, Calif.)

Salvecin (AR-301)

Human monoclonal antibody

Severe pneumonia caused by Staphylococcus aureus

Top-line phase IIa data showed no related serious adverse events at any dose level tested, and no difference in adverse effects was observed among the groups

6/6/17

Matinas Biopharma Holdings Inc. (Bedminster, N.J.)

MAT-2203

Encochleated formulation of amphotericin B

Chronic refractory mucocutaneous candidiasis infection

Interim data from the collaborative phase IIa study showed both patients met the primary endpoint, achieving ≥ 50% clinical response; MAT-2203 was well-tolerated

6/6/17

Rebiotix Inc. (Roseville, Minn.)

RBX-2660

Microbiota restoration therapy

Clostridium difficile infections

Two separate data analyses from the PUNCH CD2 trial demonstrated a single dose demonstrated a significantly better treatment response rate of preventing recurrent C. difficile infections than placebo (67% vs. 46%, respectively; p = 0.048)

6/8/17

Tetraphase Pharmaceuticals Inc. (Watertown, Mass.)

TP-6076

Synthetic, fluorocycline antibiotic

Serious and life-threatening bacterial infections

Phase I data showed it was well-tolerated and there were no serious or severe adverse events, or discontinuations due to an adverse event

6/6/17

Tetraphase Pharmaceuticals Inc. (Watertown, Mass.)

TP-271

Broad-spectrum antibiotic

Respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens

It was well-tolerated at single doses that resulted in high plasma exposures, with no clinically significant changes in lab values, ECG parameters or physical exam findings

6/6/17

Theravance Biopharma Inc. (Dublin)

Vibativ

Telavancin; antibiotic

Staphylococcus aureus

Vibativ showed its activity against S. aureus clinical isolates causing skin infections or pneumonia with concomitant bacteremia

6/6/17

Viamet Pharmaceuticals Inc. (Research Triangle Park, N.C.)

VT-1161

Oteseconazole

Recurrent yeast infections

It met the primary endpoint of a phase IIb trial, besting a placebo in all arms of the trial

6/6/17

Vical Inc. (San Diego)

VL-2397

Antifungal

Invasive aspergillosis

A phase I trial showed it to be safe and well-tolerated with favorable plasma pharmacokinetic profiles in healthy study participants

6/6/17


Notes

The date indicated refers to the BioWorld issue in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.